May 23, 2023 7:00am EDT Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases
May 22, 2023 7:00am EDT Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)
May 18, 2023 7:00am EDT Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
May 17, 2023 7:00am EDT Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression
May 8, 2023 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
May 4, 2023 7:00am EDT Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant
Apr 19, 2023 7:00am EDT Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023
Apr 17, 2023 7:00am EDT Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival
